Company Quick10K Filing
Propanc Biopharma
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 385 $4
10-Q 2020-02-14 Quarter: 2019-12-31
S-1 2019-12-12 Public Filing
10-Q 2019-11-14 Quarter: 2019-09-30
S-1 2019-05-23 Public Filing
10-Q 2019-05-15 Quarter: 2019-03-31
S-1 2019-02-25 Public Filing
10-Q 2019-02-14 Quarter: 2018-12-31
S-1 2018-10-17 Public Filing
10-Q 2018-11-13 Quarter: 2018-09-30
10-K 2018-09-17 Annual: 2018-06-30
10-Q 2018-05-10 Quarter: 2018-03-31
10-Q 2018-02-09 Quarter: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-K 2017-09-28 Annual: 2017-06-30
10-Q 2017-05-08 Quarter: 2017-03-31
10-Q 2017-02-14 Quarter: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-K 2016-09-28 Annual: 2016-06-30
10-Q 2016-05-16 Quarter: 2016-03-31
10-Q 2016-02-16 Quarter: 2015-12-31
10-Q 2015-11-16 Quarter: 2015-09-30
10-K 2015-09-30 Annual: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-Q 2015-02-17 Quarter: 2014-12-31
10-Q 2014-11-19 Quarter: 2014-09-30
10-K 2014-10-14 Annual: 2014-06-30
10-Q 2014-05-20 Quarter: 2014-03-31
10-Q 2014-02-14 Quarter: 2013-12-31
10-K 2013-10-15 Annual: 2013-06-30
10-Q 2013-05-20 Quarter: 2013-03-31
10-Q 2013-02-20 Quarter: 2012-12-31
10-K 2012-10-15 Annual: 2012-10-11
10-Q 2012-11-19 Quarter: 2012-09-30
10-Q 2012-05-21 Quarter: 2012-03-31
10-Q 2012-02-21 Quarter: 2011-12-31
8-K 2020-01-13 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-10-02 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-09-03 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-07-31 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-07-03 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-06-24 Enter Agreement, Officers, Regulation FD, Exhibits
8-K 2019-06-21 Shareholder Vote, Other Events, Exhibits
8-K 2019-05-23 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-05-14 Enter Agreement, Sale of Shares, Officers, Other Events, Exhibits
8-K 2019-02-25 Enter Agreement, Leave Agreement, Sale of Shares, Exhibits
8-K 2019-02-12 Regulation FD, Exhibits
8-K 2018-12-24 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-11-30 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-10-05 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-10-02 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-09-21 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-09-07 Regulation FD, Exhibits
8-K 2018-08-28 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-07-13 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-06-29 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-06-26 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-06-14 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-04-13 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-04-10 Regulation FD, Exhibits
8-K 2018-03-23 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-03-16 Officers
8-K 2018-03-14 Regulation FD, Exhibits
8-K 2018-02-20 Other Events, Exhibits
8-K 2018-01-22 Enter Agreement, Off-BS Arrangement, Sale of Shares, Officers, Exhibits
8-K 2017-12-29 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits

Propanc Biopharma Financials

PPCB Metrics, Comps, Filings

Annual | Quarterly

Business

As used in this Annual Report, references to the “Company,” “Propanc,” “we,” “our,” and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references to our “financial statements” are to our consolidated financial statements included elsewhere in this Annual Report except as the context otherwise requires.

We prepare our financial statements in United States dollars and in accordance with generally accepted accounting principles as applied in the United States, (“U.S. GAAP”). In this Annual Report, references to “$” and “dollars” are to United States dollars.

We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, over the last year we have conducted successful pre-clinical studies on PRP and subject to us receiving adequate financing, hope to submit a clinical trial application in the United Kingdom (the “UK”) in the first half of 2019. We intend to develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
McorpCX (MCCX) 4,085 56% -9.9 -29% 1,505 271 2,641 1,470 -434 -333 3,316
MassRoots (MSRT) 4,068 72% -0.7 -1,607% 459 8,492 27 19 -7,380 -6,192 4,067
Mr. Amazing Loans (MRAL) 3,962 0% -5.1 -22% 3,161 101 921 0 -710 -706 3,621
Determine (DTRM) 3,962 48% 0.2 -35% 39,040 44,189 24,492 11,660 -13,472 -9,605 -2,310
All American Sportpark (AASP) 3,961 -60.7 -1,803% 4 299 0 0 -65 -65 3,961
Vycor Medical (VYCO) 3,465 91% -6.4 -53% 1,086 2,353 1,127 1,020 -575 -530 3,367
Oculus (OVTZ) 5,362 -19.3 -62% 414 137 0 0 -257 -257 4,949
Propanc Biopharma (PPCB) 983 -1.0 -2,593% 198 4,739 0 -24 -5,125 -3,561 3,434
Creative Learning (CLCN) 3,848 0% 2.2 61% 2,700 5,017 4,008 0 1,644 1,644 3,559
Nuo Therapeutics (AURX) 3,796 69% -2.2 -1,173% 154 1,347 344 236 -1,810 -1,734 3,787
Patriot Gold (PGOL) 4,463 0% 25.7 9% 1,935 226 436 0 166 166 4,261
Encision (ECIA) 3,709 51% -115.6 -4% 4,148 1,933 8,055 4,147 -152 -31 3,568
Innovus Pharmaceuticals (INNV) 5,796 65% -2.1 -63% 9,514 11,510 17,966 11,617 -5,984 -3,875 8,027
Blake Insomnia Therapeutics (BKIT) 3,681 -135.2 0 237 0 0 -27 -27 3,681
Geospatial (GSPH) 3,709 70% -6.3 -736% 111 3,656 273 190 -816 -586 3,668
Visium Technologies (VISM) 0 0.0 -31,116% 3 3,141 0 0 -796 -796 -3
Cartesian (CRTN) 3,632 30% -0.4 -44% 16,522 17,461 47,555 14,053 -7,270 -5,582 2,087
GraniteShares Platinum Trust (PLTM) 5,316 12.8 7% 5,803 2 0 0 415 415 5,316
Invesco CurrencyShares Singapore Dollar Trust (FXSG) 3,628 0% -50.4 1% 3,558 1 40 0 26 26 -1,288
Fieldpoint Petroleum (FPP) 3,628 0% 13.8 -5% 4,528 6,259 1,668 0 -241 247 3,414

Balance Sheet ($'000)2012-06-302013-06-302014-06-302015-06-302015-09-302015-12-312016-03-312016-06-302017-06-302018-06-302018-06-302018-12-312019-03-312019-06-302019-09-30
Cash0088108771,1681,479121692020125107296
Accounts Receivable
Inventory
PP&E5150344413118899277
Assets4621146273051,5081,623379957171713260102198
Accounts Payable1922733502363031071593704841,1571,1571,063855917960
Long-Term Debt7824,3504,3503,4803,0973,0971,6722,0681,6572,547
Liabilities5847941,5223,6813,4874,8645,1442,9445,5376,8236,8234,6173,6734,4034,739
Stockholders' Equity-538-792-1,408-3,054-3,182-3,356-3,521-2,565-5,442-6,752-6,752-3,904-3,413-4,301-4,542
Income Statement ($'000)2012-06-302013-06-302014-06-302015-06-302015-09-302015-12-312016-03-312016-06-302017-06-302018-06-302018-06-302018-12-312019-03-312019-06-302019-09-30
Revenue0000
Cost of Revenue313128
Gross Profit-31-31-28
R&D51281341,4479721,8261,826260
SG&A11,5721,3367421,5685,4264,7392,1042,1042,326
Tax-1740000-306-179-1790
Net Income-11,434-1,443-830-3,413-9,410-7,868-7,039-7,039-5,758
Cash Flow ($'000)2012-06-302013-06-302014-06-302015-06-302015-09-302015-12-312016-03-312016-06-302017-06-302018-06-302018-06-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-170-129-226-1,426-4,499-2,051-2,178-2,178-2,060
Cash Investing00-6-120-3
Cash Financing1701283111,2824,5352,0992,3962,3962,119